Keywords

Coronavirus disease 2019 (COVID-19)Software deploymentProduction (economics)BusinessSevere acute respiratory syndrome coronavirus 2 (SARS-CoV-2)2019-20 coronavirus outbreakVirologyComputer scienceMedicineEconomicsInfectious disease (medical specialty)Outbreak

Affiliated Institutions

Related Publications

SARS-CoV-2 vaccines in development

Florian Krammer

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) was first reported in late 2019 in China and is the causative agent of the coronavirus disease 2019 (COVID-19) pande...

2020 Nature 2193 citations

Impact and effectiveness of mRNA BNT162b2 vaccine against SARS-CoV-2 infections and COVID-19 cases, hospitalisations, and deaths following a nationwide vaccination campaign in Israel: an observational study using national surveillance data

Eric J. Haas , Frederick J. Angulo , John M. McLaughlin +12 more

Following the emergency use authorisation of the Pfizer-BioNTech mRNA COVID-19 vaccine BNT162b2 (international non-proprietary name tozinameran) in Israel, the Ministry of Healt...

2021 The Lancet 1722 citations

Publication Info

Year
2021
Type
review
Volume
397
Issue
10278
Pages
1023-1034
Citations
1300
Access
Closed

External Links

View on DOI.org

Social Impact

Altmetric
PlumX Metrics

Social media, news, blog, policy document mentions

Citation Metrics

1300
OpenAlex

Cite This

Olivier J. Wouters, Kenneth C. Shadlen, Maximilian Salcher‐Konrad et al. (2021). Challenges in ensuring global access to COVID-19 vaccines: production, affordability, allocation, and deployment. The Lancet , 397 (10278) , 1023-1034. https://doi.org/10.1016/s0140-6736(21)00306-8

Identifiers

DOI
10.1016/s0140-6736(21)00306-8